Aeglea Bio Therapeutics Inc
Change company Symbol lookup
Select an option...
AGLE Aeglea Bio Therapeutics Inc
GME GameStop Corp
XELA Exela Technologies Inc
ARKK ARK Innovation ETF
NVVEW Nuvve Holding Equity Warrants Exp 19 March 2026 *W EXP 03/19/2026
BEPH Brookfield BRP Holdings (Canada) Inc
CHKP Check Point Software Technologies Ltd
FDX FedEx Corp
VLON Vallon Pharmaceuticals Inc
HCNEU Jaws Hurricane Acquisition Corp
Go

Health Care : Biotechnology |
Company profile

Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing human enzyme therapeutics to benefit people with rare metabolic diseases. The Company’s product candidates include pegzilarginase and AGLE-177. The Company's lead product candidate, pegzilarginase, is a recombinant human arginase one that enzymatically degrades the amino acid arginine to lower arginine levels in patients with Arginase one Deficiency. Its engineered pegzilarginase with modifications that enhance the stability and arginine-degrading activity of the enzyme in human plasma. The Company is evaluating Pegzilarginase in a global pivotal Phase III PEACE (Pegzilarginase Effect on Arginase one Deficiency Clinical Endpoints) trial and in a Phase II open-label extension study for patients with Arginase One Deficiency. Its AGLE-177, is a novel PEGylated, or polyethylene glycol modified, human enzyme engineered to reduce Homocystinuria.

Closing Price
$6.00
Day's Change
-0.17 (-2.76%)
Bid
--
Ask
--
B/A Size
--
Day's High
6.21
Day's Low
5.90
Volume
(Average)
Volume:
157,454

10-day average volume:
174,612
157,454

Tesla earnings preview: Wall Street hopes dark clouds are 'in the rearview mirror'

8:35 am ET October 18, 2021 (MarketWatch)
Print

Claudia Assis

Wall Street is upbeat about Tesla Inc.'s quarterly earnings, slated for Wednesday after the bell, hoping that record sales and price increases will have offset higher costs related to supply-chain snags.

Tesla (TSLA) will have a call with analysts right after it releases the third-quarter results on Wednesday, scheduled for 5:30 Eastern, and it will be webcast.

"We expect Tesla's recently reported strong delivery numbers and higher vehicle pricing to more than offset any added costs from supply chain challenges (e.g. chip shortages, higher freight costs, and increasing commodity costs) in the quarter," Mark Delaney with Goldman Sachs said in a recent note.

Tesla will be reporting earnings from Austin, Texas, for the first time. Chief Executive Elon Musk announced last week that the company was moving headquarters to Austin from Palo Alto, Calif., even though it still plans on investing in and expanding its California plant.

Tesla just had its annual shareholder meeting, and that might be the last investors will hear directly from Musk in a while.

At Tesla's meeting post second-quarter results in late July, Musk surprised Wall Street by saying he would unlikely be on future Tesla earnings calls, "unless there's something important I need to say," he told analysts and others. It is unclear whether he'd be on the call on Wednesday.

Here's what to expect:

Earnings: The FactSet consensus calls for Tesla to report adjusted per-share earnings of $1.58 for the quarter. That would compare with adjusted earnings of 76 cents a share in the third quarter of 2020.

Estimize, a crowdsourcing platform that gathers estimates from Wall Street analysts as well as buy-side analysts, fund managers, company executives, academics and others, is expecting an adjusted profit of $1.79 a share for Tesla.

Revenue: The analysts polled by FactSet are calling for sales of $13.7 billion for Tesla, which would compare with $8.8 billion in the third quarter of 2020. Estimize is expected $13.9 billion of revenue.

Stock price: Tesla shares have gained 18% this year, compared with gains of around 19% for the S&P 500 index. The stock has outperformed the index by a large margin in the past three months, however: a 28% advance compared with a 3% advance for the S&P.

What else to expect: Musk updated investors about the Cybertruck at the shareholder meeting, saying that the futuristic-looking all-electric pickup truck, will enter production next year and hit volume production by 2023.

Musk described a "constant struggle" to get enough chips and other auto parts for the truck and other Tesla vehicles, saying that a respite for the worst of the shortages is likely by 2023.

Related: More electric pickup trucks are coming to market. The question now is who will buy them?

Investors will want to hear more about that prediction and also details on how the current shortages continues to affect the car maker.

Sales in China are also at the top of the list of issue investors will want to get details from.

Tesla had a rocky first few months on 2021 in China, where orders for its vehicles fell and where Tesla faced a backlash over how it handled consumer concerns about the safety and quality of its cars. Tesla also has had to grapple with more competition from Chinese EV makers such as Nio Inc. (NIO)

No so anymore, Dan Ives of Wedbush said in his note earlier in the week.

"After softer China sales earlier this year, Tesla is seeing massive demand momentum" into an year-end with "robust sales" in the month of September in China and "a clear positive for the bulls," he said. The dark clouds are "in the rearview mirror," Ives said.

The bump in sales for Tesla in China "is a clear indicator of this green tidal wave taking hold for Musk & Co. across the board," he said.

-Claudia Assis

	

(END) Dow Jones Newswires

October 18, 2021 08:35 ET (12:35 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2021. All rights reserved.